Fruman DA - Search Results

1

Targeting mTOR for the treatment of B cell malignancies.

Lee JS, Vo TT, Fruman DA. Lee JS, et al. Among authors: fruman da. Br J Clin Pharmacol. 2016 Nov;82(5):1213-1228. doi: 10.1111/bcp.12888. Epub 2016 Mar 3. Br J Clin Pharmacol. 2016. PMID: 26805380 Free PMC article. Review.

2

Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling.

Fruman DA. Fruman DA. Curr Opin Immunol. 2004 Jun;16(3):314-20. doi: 10.1016/j.coi.2004.03.014. Curr Opin Immunol. 2004. PMID: 15134780 Review.

3

T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling.

Deane JA, Kharas MG, Oak JS, Stiles LN, Luo J, Moore TI, Ji H, Rommel C, Cantley LC, Lane TE, Fruman DA. Deane JA, et al. Among authors: fruman da. Blood. 2007 Apr 1;109(7):2894-902. doi: 10.1182/blood-2006-07-038620. Blood. 2007. PMID: 17164340 Free PMC article.

4

Distinct signaling mechanisms activate the target of rapamycin in response to different B-cell stimuli.

Donahue AC, Fruman DA. Donahue AC, et al. Among authors: fruman da. Eur J Immunol. 2007 Oct;37(10):2923-36. doi: 10.1002/eji.200737281. Eur J Immunol. 2007. PMID: 17724683 Free article.

5

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA. Kharas MG, et al. Among authors: fruman da. J Clin Invest. 2008 Sep;118(9):3038-50. doi: 10.1172/JCI33337. J Clin Invest. 2008. PMID: 18704194 Free PMC article.

6

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA. Janes MR, et al. Among authors: fruman da. Nat Med. 2010 Feb;16(2):205-13. doi: 10.1038/nm.2091. Epub 2010 Jan 13. Nat Med. 2010. PMID: 20072130 Free PMC article.

7

Targeting TOR dependence in cancer.

Janes MR, Fruman DA. Janes MR, et al. Among authors: fruman da. Oncotarget. 2010 May;1(1):69-76. doi: 10.18632/oncotarget.110. Oncotarget. 2010. PMID: 20657741 Free PMC article.

8

Target of rapamycin signaling in leukemia and lymphoma.

Vu C, Fruman DA. Vu C, et al. Among authors: fruman da. Clin Cancer Res. 2010 Nov 15;16(22):5374-80. doi: 10.1158/1078-0432.CCR-10-0480. Epub 2010 Sep 8. Clin Cancer Res. 2010. PMID: 20826559 Review.

9

Akt and mTOR in B Cell Activation and Differentiation.

Limon JJ, Fruman DA. Limon JJ, et al. Among authors: fruman da. Front Immunol. 2012 Aug 6;3:228. doi: 10.3389/fimmu.2012.00228. eCollection 2012. Front Immunol. 2012. PMID: 22888331 Free PMC article.

10

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.

Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA. Janes MR, et al. Among authors: fruman da. Leukemia. 2013 Mar;27(3):586-94. doi: 10.1038/leu.2012.276. Epub 2012 Oct 1. Leukemia. 2013. PMID: 23090679 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

147 results

Search Page